

## Cell Line Data Sheet for SK-N-FI

**Disease:** Neuroblastoma  
**Phase of Therapy:** Post-Chemotherapy (Progressive Disease)  
**Treatment:**  
**Disease Stage:** 4  
**Gender:** Male  
**Age at diagnosis:** 132 months  
**Race:** N/A  
**Age at sample collection:** N/A  
**Source of Culture:** Bone Marrow  
**Primary Tumor Site:** Brain  
**Date Established:** 1979

**MYCN Patient:** Non-Amplified  
**MYCN Cell line:** N/A  
**TH mRNA:** Positive  
**p53 functionality:** N/A  
**Telomere Mechanism** N/A  
**ALK:** WT

**IC90 (DIMSCAN\*):**      CBDCA (µg/ml)    CDDP (µg/ml)    DOX (ng/ml)    ETOP (ng/ml)    L-PAM (µg/ml)  
 \*see reference 4      N/A                    N/A                    N/A                    N/A                    N/A  
 CBDCA, carboplatin; CDDP, cisplatin; DOX, doxorubicin; ETOP, etoposide; L-PAM, melphalan

**Growth Conditions:** Please see Protocols section at <https://www.cccells.org/protocols.php>  
 5% CO<sub>2</sub>, 20% O<sub>2</sub>, 37.0°C

**Media Formulation:** Please see Protocols section at <https://www.cccells.org/protocols.php>  
 Cells are grown in a base medium of Iscove's Modified Dulbecco's Medium plus the following supplements (to a final concentration): 20% Fetal Bovine Serum, 4mM L-Glutamine, 1X ITS (5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenous acid)

**Doubling Time:** N/A hours  
**Growth Properties:** Epithelial cells, mostly adherent with some suspended

**STR Profile:** May be obtained at <https://strdb.cccells.org/>

**Notes:**

All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO. Each vial label contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen. All cell lines are validated with original patient sample by STR analysis.



---

## Cell Line Data Sheet for SK-N-FI

---

### References:

1. Reynolds CP, Brodeur GM, Tomayko MM, Donner L, Helson L, Seeger RC, Triche TJ: Biological classification of cell lines derived from human extra-cranial neural tumors. *Prog Clin Biol Res.* 271:291-306, 1988. PubMed ID: 3406003  
<https://pubmed.ncbi.nlm.nih.gov/3406003/>
2. Wang Y, Einhorn P, Triche TJ, Seeger RC, Reynolds CP. Expression of Protein Gene Product 9.5 and Tyrosine Hydroxylase in Childhood Small Round Cell Tumors. *Clin Cancer Res.* 6, 551-558, 2000. PubMed ID: 10690538  
<https://clincancerres.aacrjournals.org/content/6/2/551.long>
3. Thompson PM, Maris JM, Hogarty MD, Seeger RC, Reynolds CP, Brodeur GM, White PS. Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at Other Tumor Suppressor Loci in Neuroblastoma. *Cancer Res.* 61, 679-686, 2001. PubMed ID: 11212268  
<https://cancerres.aacrjournals.org/content/61/2/679.long>
4. Kang MH, Smith MA, Morton CL, Keshlava N, Houghton PJ, Reynolds CP. National Cancer Institute Pediatric Preclinical Testing Program: Model Description for In Vitro Cytotoxicity Testing. *Pediatr Blood Cancer.* 56: 239-249, 2011. PubMed ID: 20922763 ([www.PPTPinvitro.org](http://www.PPTPinvitro.org))  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005554/>



---

## Cell Line Data Sheet for SK-N-FI

---

**Cell Line Name:** SK-N-FI

Low confluency (10x magnification)

High confluency (10x magnification)

Low confluency (20x magnification)

High confluency (20x magnification)